Angioimmunoblastic lymphadenopathy with dysproteinemia. Complete remission with cisplatin-based chemotherapy.
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is classified as a nonmalignant condition, yet the mortality associated with the disease rivals most malignancies. Although a leading standard text recommends prednisone as initial management, there has been increasing evidence that combination chemotherapy is the best initial treatment. The patient described here achieved a complete remission with cisplatin-based therapy but later died of pneumonia, perhaps because pathogens important in infections in AILD were not covered. Specific recommendations for management are discussed.
D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006942:Hypergammaglobulinemia / Q000150:complications / Q000188:drug therapy; D007119:Immunoblastic Lymphadenopathy / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin